GlassScriptPhysician profile
Brittani E Moeller
NPI 1487069985
$2,563.25
in general payments reported to CMS, 2019-2025
33 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.37 · 2020: $515 · 2021: $692 · 2022: $364 · 2023: $288 · 2024: $327 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $310.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $283.92 | 2020-2024 | |
| Lilly USA, LLC | $239.07 | 2019-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $200.50 | 2020-2021 | |
| Amgen INC. | $181.44 | 2019-2024 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $172.50 | 2021-2025 | Shingrix, Bexsero, Arexvy |
| Otsuka America Pharmaceutical, INC. | $137.47 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $122.22 | 2022-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $98.18 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.83 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $89.43 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $62.76 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.88 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $51.64 | 2020-2022 | |
| Abbott Laboratories | $45.15 | 2024-2025 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $43.25 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Pfizer INC. | $34.01 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $30.44 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $30.14 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.67 | 2022 | |
| Merck Sharp & Dohme LLC | $28.53 | 2020-2022 | |
| Dexcom, INC. | $27.94 | 2021-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $27.67 | 2024 | Inspire |
| Organon LLC | $27.66 | 2022-2023 | Nexplanon |
| Eisai INC. | $26.31 | 2020 | |
| Janssen Biotech, INC. | $17.80 | 2023 | Stelara |
| Exact Sciences Corporation | $17.13 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $14.43 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $13.70 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.23 | 2023 | Seglentis, Livalo |
| Biohaven Pharmaceuticals, INC. | $12.35 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.06 | 2020 | |
| Genentech USA, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittani Moeller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.